ReviewMolecular neurobiology2008
The ART of loss: Abeta imaging in the evaluation of Alzheimer's disease and other dementias.
Review in Molecular neurobiology, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed.
- Comparison of 11C-PiB and 18F-florbetaben for Aβ imaging in ageing and Alzheimer's disease.European journal of nuclear medicine and molecular imaging · 2012Trial
- A brief history of Aβ imaging.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025Review
- Tau Imaging: Use and Implementation in New Diagnostic and Therapeutic Paradigms for Alzheimer's Disease.Geriatrics (Basel, Switzerland) · 2025Review
- Molecular Imaging Approaches in Dementia.Radiology · 2021Review
- Temporal and anatomical distribution ofBMC veterinary research · 2020Article
- Calcium Signaling in ß-cell Physiology and Pathology: A Revisit.International journal of molecular sciences · 2019Review
- Bax inhibitor 1 is a γ-secretase-independent presenilin-binding protein.Proceedings of the National Academy of Sciences of the United States of America · 2019Article
- Presenilin mutations deregulate mitochondrial CaeLife · 2018Article
- Imaging tau and amyloid-β proteinopathies in Alzheimer disease and other conditions.Nature reviews. Neurology · 2018Review
- Analysis of 138 pathogenic mutations in presenilin-1 on the in vitro production of Aβ42 and Aβ40 peptides by γ-secretase.Proceedings of the National Academy of Sciences of the United States of America · 2017Article
- Insight into the Molecular Imaging of Alzheimer's Disease.International journal of biomedical imaging · 2016Review
- Untangling tau imaging.Alzheimer's & dementia (Amsterdam, Netherlands) · 2016Review
- Article
- Molecular imaging of neuropsychiatric symptoms in Alzheimer's and Parkinson's disease.Neuroscience and biobehavioral reviews · 2015Review
- Differences in functional brain connectivity alterations associated with cerebral amyloid deposition in amnestic mild cognitive impairment.Frontiers in aging neuroscience · 2015Article
- A survey of FDG- and amyloid-PET imaging in dementia and GRADE analysis.BioMed research international · 2014Review
- Assessing THK523 selectivity for tau deposits in Alzheimer's disease and non-Alzheimer's disease tauopathies.Alzheimer's research & therapy · 2014Article
- Is the amyloid hypothesis of Alzheimer's disease therapeutically relevant?The Biochemical journal · 2012Review
- The prognostic value of amyloid imaging.European journal of nuclear medicine and molecular imaging · 2012Review
- Assessment of mild dementia with amyloid and dopamine terminal positron emission tomography.Brain : a journal of neurology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Molecular neuroimaging based on annihilation radiation tomographic (ART) techniques such as positron emission tomography (PET), in conjunction with related biomarkers in plasma and cerebrospinal fluid (CSF), are proving valuable in the early and differential diagnosis of Alzheimer's disease (AD). With the advent of new therapeutic strategies aimed at reducing beta-amyloid (Abeta) burden in the brain to potentially prevent or delay functional and irreversible cognitive loss, there is increased interest in developing agents that allow assessment of Abeta burden in vivo. Abeta burden as assessed by molecular imaging matches histopathological reports of Abeta plaque distribution in aging and dementia and appears more accurate than FDG for the diagnosis of AD. Abeta imaging is also a very powerful tool in the differential diagnosis of AD from fronto-temporal dementia (FTD). Although Abeta burden as assessed by PET does not correlate with measures of cognitive decline in AD, it does correlate with memory impairment and rate of memory decline in mild cognitive impairment (MCI) and healthy older subjects. Approximately 30% of asymptomatic controls present cortical (11)C-PiB retention. These observations suggest that Abeta deposition is not part of normal ageing, supporting the hypothesis that Abeta deposition occurs well before the onset of symptoms and is likely to represent preclinical AD. Further longitudinal observations are required to confirm this hypothesis and to better elucidate the role of Abeta deposition in the course of Alzheimer's disease.
Indexed as
Identifiers
18690556What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.